NASDAQ:ETON Eton Pharmaceuticals Q4 2024 Earnings Report $19.93 +0.13 (+0.66%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$19.94 +0.01 (+0.05%) As of 10/3/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Eton Pharmaceuticals EPS ResultsActual EPS-$0.02Consensus EPS -$0.02Beat/MissMet ExpectationsOne Year Ago EPSN/AEton Pharmaceuticals Revenue ResultsActual Revenue$11.65 millionExpected Revenue$10.53 millionBeat/MissBeat by +$1.12 millionYoY Revenue GrowthN/AEton Pharmaceuticals Announcement DetailsQuarterQ4 2024Date3/18/2025TimeBefore Market OpensConference Call DateTuesday, March 18, 2025Conference Call Time10:00AM ETUpcoming EarningsEton Pharmaceuticals' Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Eton Pharmaceuticals Earnings HeadlinesEton Pharmaceuticals (NASDAQ:ETON) Hits New 1-Year High on Analyst UpgradeSeptember 30, 2025 | americanbankingnews.comEton Pharmaceuticals (NASDAQ:ETON) Raised to "Buy" at Wall Street ZenSeptember 28, 2025 | americanbankingnews.comIs $1M Enough to Retire Comfortably in 2025?Many people hope to retire with $1 million in savings, but how long will it really last? The answer can depend on your retirement age, life expectancy and the kind of lifestyle you plan to live. For some people, $1 million may be more than enough for a comfortable retirement. For others, it might not be enough.October 4 at 2:00 AM | SmartAsset (Ad)Top Growth Companies With Strong Insider OwnershipSeptember 24, 2025 | finance.yahoo.comImplied Volatility Surging for Eton Pharmaceuticals Stock OptionsSeptember 22, 2025 | msn.comWe Might See A Profit From Eton Pharmaceuticals, Inc. (NASDAQ:ETON) SoonSeptember 22, 2025 | finance.yahoo.comSee More Eton Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Eton Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eton Pharmaceuticals and other key companies, straight to your email. Email Address About Eton PharmaceuticalsEton Pharmaceuticals (NASDAQ:ETON) is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings. The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis. Eton gained U.S. Food and Drug Administration approval for several abbreviated new drug applications (ANDAs) and new drug applications (NDAs), enabling it to bring both generic and specialty branded medicines to market. Its development pipeline features additional hormone replacement therapies and other complex dosage forms intended to broaden its reach in endocrine and rare disease markets. Eton Pharmaceuticals serves patients and healthcare providers across the United States through strategic partnerships with wholesalers, specialty pharmacies and healthcare institutions. The company employs a network of contract manufacturing organizations to ensure product quality and supply chain efficiency. With a focus on regulatory compliance, timely product launches and niche market development, Eton continues to pursue opportunities that align with its mission of improving care for patients with limited treatment options.View Eton Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings Upcoming Earnings PepsiCo (10/9/2025)Fastenal (10/13/2025)BlackRock (10/14/2025)Citigroup (10/14/2025)The Goldman Sachs Group (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)Wells Fargo & Company (10/14/2025)ASML (10/15/2025)Abbott Laboratories (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
